Edwards Lifesciences Corporation $EW Shares Sold by Adage Capital Partners GP L.L.C.

Key Points

• Adage Capital Partners GP L.L.C. reduced its stake in Edwards Lifesciences Corporation by 63%, owning about $32.85 million worth of shares following the sale of 770,627 shares.
• Multiple hedge funds have also increased their positions in Edwards Lifesciences, indicating a strong interest among institutional investors, who now own 79.46% of the stock.
• Analysts have a consensus rating of "Moderate Buy" for Edwards Lifesciences, with prices targets ranging from $80 to $100, reflecting positive sentiment around the company's potential for growth.

Adage Capital Partners GP L.L.C. lowered its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 63.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 453,266 shares of the medical research company's stock after selling 770,627 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 0.08% of Edwards Lifesciences worth $32,853,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Jennison Associates LLC raised its stake in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after acquiring an additional 2,576,383 shares during the period. Deutsche Bank AG increased its stake in Edwards Lifesciences by 10.4% in the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock worth $511,044,000 after buying an additional 652,923 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Edwards Lifesciences by 8.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock worth $482,621,000 after buying an additional 513,468 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in Edwards Lifesciences by 24.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 4,615,163 shares of the medical research company's stock worth $341,661,000 after buying an additional 921,500 shares during the period. Finally, Nuveen LLC purchased a new position in Edwards Lifesciences in the 1st quarter worth about $330,881,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the topic of several recent analyst reports. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Robert W. Baird raised their price target on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Argus upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Finally, Piper Sandler increased their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock worth $1,698,844 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Down 0.8%

Shares of EW stock traded down $0.66 on Monday, hitting $80.28. 3,043,388 shares of the stock traded hands, compared to its average volume of 4,450,066. The firm's 50-day moving average price is $78.77 and its two-hundred day moving average price is $75.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market capitalization of $47.13 billion, a PE ratio of 11.55, a PEG ratio of 3.90 and a beta of 1.07. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the previous year, the company posted $0.70 EPS. The company's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.